Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Raghav, Kanwal Pratap Singh
34  Ergebnisse:
Personensuche X
?
1

Regorafenib plus nivolumab in patients with mismatch repair..:

Fakih, Marwan ; Raghav, Kanwal Pratap Singh ; Chang, David Z....
eClinicalMedicine.  58 (2023)  - p. 101917 , 2023
Link: https://doi.org/10.1016/..
 
?
2

Benchmarking Outcomes for Definitive Treatment of Young-Ons..:

Taku, Nicolette ; Yi-Qian, Y. Nancy ; Chang, George J....
Clinical Colorectal Cancer.  21 (2022)  1 - p. e28-e37 , 2022
Link: https://doi.org/10.1016/..
 
?
3

Retrospective Analysis of Taxane-Based Therapy in Small Bow..:

Aldrich, Jeffrey D. ; Raghav, Kanwal Pratap Singh ; Varadhachary, Gauri R...
The Oncologist.  24 (2018)  6 - p. e384-e386 , 2018
Link: https://doi.org/10.1634/..
 
?
4

Joint prognostic effect of obesity and chronic systemic inf..:

Shah, Manasi S. ; Fogelman, David R. ; Raghav, Kanwal Pratap Singh...
Cancer.  121 (2015)  17 - p. 2968-2975 , 2015
Link: https://doi.org/10.1002/..
 
?
5

Obesity Early in Adulthood Increases Risk but Does Not Affe..:

Hassan, Manal M. ; Abdel-Wahab, Reham ; Kaseb, Ahmed...
Gastroenterology.  149 (2015)  1 - p. 119-129 , 2015
Link: https://doi.org/10.1053/..
 
?
6

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-..:

Raghav, Kanwal Pratap Singh ; Siena, Salvatore ; Takashima, Atsuo...
boreal:277898.  , 2023
Link: http://hdl.handle.net/20..
 
?
7

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-..:

Raghav, Kanwal Pratap Singh ; Siena, Salvatore ; Takashima, Atsuo...
boreal:277898.  , 2023
Link: http://hdl.handle.net/20..
 
?
8

Trastuzumab deruxtecan in patients with HER2-overexpressing..:

Raghav, Kanwal Pratap Singh ; Yoshino, Takayuki ; Guimbaud, Rosine...
boreal:277922.  , 2022
Link: http://hdl.handle.net/20..
 
?
9

Trastuzumab deruxtecan in patients with HER2-overexpressing..:

Raghav, Kanwal Pratap Singh ; Yoshino, Takayuki ; Guimbaud, Rosine...
boreal:277922.  , 2022
Link: http://hdl.handle.net/20..
 
?
10

Benchmarking Outcomes for Definitive Treatment of Young-Ons..:

Taku, Nicolette ; You, Y. Nancy ; Chang, George J...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917971/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
11

Trastuzumab deruxtecan in patients with HER2-overexpressing..:

Raghav, Kanwal Pratap Singh ; Yoshino, Takayuki ; Guimbaud, Rosine...
boreal:277926.  , 2021
Link: http://hdl.handle.net/20..
 
?
12

Trastuzumab deruxtecan in patients with HER2-overexpressing..:

Raghav, Kanwal Pratap Singh ; Yoshino, Takayuki ; Guimbaud, Rosine...
boreal:277926.  , 2021
Link: http://hdl.handle.net/20..
 
?
13

Retrospective Analysis of Taxane‐Based Therapy in Small Bow..:

Aldrich, Jeffrey D ; Raghav, Kanwal Pratap Singh ; Varadhachary, Gauri R..
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656507/.  , 2018
Link: http://www.ncbi.nlm.nih...
 
?
14

Phase II trial of bevacizumab and erlotinib as a second-lin..:

Kaseb, Ahmed O ; Morris, Jeffrey S ; Iwasaki, Michiko...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760665/.  , 2016
Link: http://www.ncbi.nlm.nih...
 
?
15

Joint prognostic effect of obesity and chronic systemic inf..:

Shah, Manasi S ; Fogelman, David R ; Raghav, Kanwal Pratap Singh...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545691/.  , 2015
Link: http://www.ncbi.nlm.nih...
 
1-15